MPL and autoimmune thrombocytopenic purpura: Eltrombopag is a thrombopoietin receptor agonist that has been frequently used for the treatment of chronic ITP for over a decade but it is rarely used in patients with newly diagnosed ITP.[10–13] The outcomes of eltrombopag treatment as the first-line treatment for children with newly diagnosed ITP were not reported, except for one patient.[14] We first described in detail the use of eltrombopag in a newly diagnosed steroid and IVIG nonresponsive pediatric ITP patient.